Black Diamond Therapeutics Inc

-0.22 (-3.54%)
Earnings Announcements

Black Diamond Therapeutics Reports Qtrly Net Loss Per Share Of $0.97

Published: 11/08/2021 14:27 GMT
Black Diamond Therapeutics Inc (BDTX) - Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update.
Black Diamond - Cash, Cash Equivalents, and Investments of $235.0 Million As of Sept 30, 2021, Expected to Be Sufficient to Fund Operations Into H2 2023.
Qtrly Net Loss per Share $0.97.
Q3 Earnings per Share View $-0.98 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.00

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.01

More details on our Analysts Page.